Arbutus Biopharma (ABUS) Short Interest Ratio & Short Volume

Short interest is the volume of Arbutus Biopharma shares that have been sold short but have not yet been closed out or covered. As of May 31st, investors have sold 12,750,000 shares of ABUS short. 7.01% of Arbutus Biopharma's shares are currently sold short. Learn More on Arbutus Biopharma's current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. ABUS shares currently have a short interest ratio of 14.0. Learn More on Arbutus Biopharma's short interest ratio.

As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Arbutus Biopharma: Jane Street Group LLC, Caption Management LLC, Nomura Holdings Inc., and Simplex Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 7.01% of Arbutus Biopharma's floating shares are currently sold short.

Arbutus Biopharma saw a increase in short interest during the month of May. As of May 31st, there was short interest totaling 12,750,000 shares, an increase of 10.9% from the previous total of 11,500,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

7.01% of Arbutus Biopharma's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Arbutus Biopharma: Lyell Immunopharma, Inc. (8.81%), Apellis Pharmaceuticals, Inc. (21.59%), Organon & Co. (6.75%), HUTCHMED (China) Limited (0.28%), ImmunityBio, Inc. (62.35%), Amneal Pharmaceuticals, Inc. (2.93%), Xenon Pharmaceuticals Inc. (4.68%), Mirum Pharmaceuticals, Inc. (16.37%), Arrowhead Pharmaceuticals, Inc. (11.03%), NewAmsterdam Pharma (10.54%),

As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($64.96 billion), Invesco QQQ ($27.88 billion), iShares Russell 2000 ETF ($19.94 billion), iShares 20+ Year Treasury Bond ETF ($9.69 billion), Strategy Incorporated ($8.58 billion), SPDR S&P Biotech ETF ($5.72 billion), Invesco S&P 500 Equal Weight ETF ($5.45 billion), iShares iBoxx $ Investment Grade Corporate Bond ETF ($4.70 billion), Charter Communications, Inc. ($4.54 billion), and Industrial Select Sector SPDR Fund ($4.49 billion). View all of the most shorted stocks.

Short selling ABUS is an investing strategy that aims to generate trading profit from Arbutus Biopharma as its price is falling. ABUS shares are trading down $0.05 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Arbutus Biopharma occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of ABUS, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ABUS, twice per month. The most recent reporting period available is May, 31 2025.